206 related articles for article (PubMed ID: 18242)
1. Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia.
Johnson DA
Br J Hosp Med; 1977 Jun; 17(6):546-58. PubMed ID: 18242
[No Abstract] [Full Text] [Related]
2. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
Dencker SJ
J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
[TBL] [Abstract][Full Text] [Related]
3. Early hospital experience with fluphenazine decanoate.
Small JG; Kellams J
Dis Nerv Syst; 1974 Oct; 35(10):453-6. PubMed ID: 17894058
[TBL] [Abstract][Full Text] [Related]
4. Depot fluphenazine: risk/benefit ratio.
Glazer WM
J Clin Psychiatry; 1984 May; 45(5 Pt 2):28-35. PubMed ID: 6370986
[TBL] [Abstract][Full Text] [Related]
5. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
Johnson DA
J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
[TBL] [Abstract][Full Text] [Related]
6. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics.
Möller HJ; Kissling W
Clin Neuropharmacol; 1986; 9 Suppl 4():259-62. PubMed ID: 2882841
[No Abstract] [Full Text] [Related]
7. Antipsychotic medication: clinical guidelines for maintenance therapy.
Johnson DA
J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
[TBL] [Abstract][Full Text] [Related]
8. Depot neuroleptic therapy: an underutilized treatment option.
Glazer WM; Kane JM
J Clin Psychiatry; 1992 Dec; 53(12):426-33. PubMed ID: 1362569
[TBL] [Abstract][Full Text] [Related]
9. Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
Hogarty GE
J Clin Psychiatry; 1984 May; 45(5 Pt 2):36-42. PubMed ID: 6143746
[TBL] [Abstract][Full Text] [Related]
10. [Prolonged action neuroleptics (review of the foreign literature)].
Obukhov GA
Zh Nevropatol Psikhiatr Im S S Korsakova; 1975; 75(2):285-95. PubMed ID: 235182
[No Abstract] [Full Text] [Related]
11. Therapy with injectable fluphenazines.
Ayd FJ
Curr Psychiatr Ther; 1976; 16():177-89. PubMed ID: 991628
[No Abstract] [Full Text] [Related]
12. Experience with depot neuroleptics in ambulatory practice.
Fiolet J
Acta Psychiatr Belg; 1981; 81(2):182-8. PubMed ID: 6117188
[TBL] [Abstract][Full Text] [Related]
13. Depot neuroleptics: side effects and safety.
Marder SR
J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):24S-29S. PubMed ID: 2870089
[TBL] [Abstract][Full Text] [Related]
14. Side effects of depot fluphenazines.
Ayd FJ
Adv Biochem Psychopharmacol; 1974; 9(0):301-9. PubMed ID: 4599435
[No Abstract] [Full Text] [Related]
15. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
[TBL] [Abstract][Full Text] [Related]
16. The depot fluphenazines: a reappraisal after 10 years' clinical experience.
Ayd FJ
Am J Psychiatry; 1975 May; 132(5):491-500. PubMed ID: 1091162
[No Abstract] [Full Text] [Related]
17. Compliance in the long-term treatment of schizophrenia.
Kane JM; Borenstein M
Psychopharmacol Bull; 1985; 21(1):23-7. PubMed ID: 2858907
[No Abstract] [Full Text] [Related]
18. Comparison of antipsychotic depot injections in the maintenance treatment of schizophrenia.
Carney MW; Sheffield BF
Br J Psychiatry; 1976 Nov; 129():476-81. PubMed ID: 990663
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of schizophrenia].
Houy-Durand E; Thibaut F
Rev Prat; 2002 Jun; 52(11):1213-20. PubMed ID: 12148207
[TBL] [Abstract][Full Text] [Related]
20. A controlled one-year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Evaluation of results at 6 and 12 months' trial.
Dencker SJ; Frankenberg K; Malm U; Zell B
Acta Psychiatr Scand Suppl; 1973; 241():101-18. PubMed ID: 4147508
[No Abstract] [Full Text] [Related]
[Next] [New Search]
